Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC-Reference-Cited by-同舟云学术

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC

Published:2017-02 Issue: Volume:104 Page:119-125
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Wu Yi-Long,Saijo Nagahiro,Thongprasert Sumitra,Yang J. C.-H.,Han Baohui,Margono Benjamin,Chewaskulyong Busayamas,Sunpaweravong Patrapim,Ohe Yuichiro,Ichinose Yukito,Yang Jin-Ji,Mok Tony S.K.,Young Helen,Haddad Vincent,Rukazenkov Yuri,Fukuoka Masahiro

Funder

AstraZeneca. IRESSA

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference19 articles.

1. World Health Organization. GLOBOCAN 2012: Estimated Cancer Incidence Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx (Accessed 2 August 2016).

2. NICE, EGFR-TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer. http://www.nice.org.uk/guidance/dg9, (Accessed 2 August 2016).

3. National Comprehensive Cancer Network Practice guidelines in oncology −version V.4.2016 (non-small-cell lung cancer). http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf, (Accessed 2 August 2016).

4. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap);Dearden;Ann. Oncol.,2013

5. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER);Shi;J. Thorac. Oncol.,2014

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. m⁶A reader YTHDF3 triggers the progression of hepatocellular carcinoma through the YTHDF3/m⁶A‐EGFR/STAT3 axis and EMT;Molecular Carcinogenesis;2023-07-14

2. Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer;BMJ Open Respiratory Research;2023-06

3. Targeting the epidermal growth factor receptor following complete surgical resection in patients with early-stage non-small cell lung cancer;Expert Opinion on Pharmacotherapy;2023-05-27

4. Identification of EGFR mutation status in male patients with non-small-cell lung cancer: role of 18F-FDG PET/CT and serum tumor markers CYFRA21-1 and SCC-Ag;EJNMMI Research;2023-04-04

5. And Still They Come Over Troubled Waters: Can Asia’s Third-Generation EGFR Tyrosine Kinase Inhibitors (Furmonertinib, Aumolertinib, Rezivertinib, Limertinib, Befotertinib, SH-1028, and Lazertinib) Affect Global Treatment of EGFR+ NSCLC;Journal of Thoracic Oncology;2022-10